Post-pandemic and flush with cash, Vir eyes new frontiers in oncology and neurology
Vir Biotechnology is best known for jumping into action during a crisis: It helped create an antibody during the Ebola outbreak and sprinted to make a Covid-19 treatment with GSK in the earliest days of the pandemic.
But now, as its Covid sales dwindle, the US and Swiss biotech is on the hunt for ways to move into “other viral-associated diseases, or anywhere where immune targeting is important, such as in oncology and neurology,” CEO Marianne De Backer told Endpoints News. “You will, in the future, see some examples of that.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.